US stock futures flounder amid tech weakness, Fed caution
In a recent transaction, Keck Kim, a director at Evolent Health, Inc. (NYSE:EVH), acquired 10,540 shares of the company’s Class A common stock. The shares were purchased on March 7, 2025, at a weighted average price of $9.44 per share, amounting to a total investment of $99,497. The purchase price ranged from $9.09 to $9.47 per share. Following this transaction, Kim holds a total of 39,522 shares directly.This insider purchase comes as EVH trades near $9, down over 70% from its 52-week high of $34.84. According to InvestingPro analysis, the stock appears undervalued, with analysts setting price targets between $12-$20. This aligns with broader management confidence, as InvestingPro data shows aggressive share buybacks by the company. Get deeper insights into insider trading patterns and 10+ additional ProTips with an InvestingPro subscription.
In other recent news, Evolent Health reported fourth-quarter results that did not meet analyst expectations, with adjusted earnings per share at -$0.02, missing the projected $0.07. Revenue for the quarter reached $646.5 million, falling short of the $652.2 million forecast but still marking a 16.3% year-over-year increase. The company posted full-year 2024 revenue of $2.55 billion, a 30.1% rise from 2023, yet its 2025 revenue guidance of $2.06 billion to $2.11 billion disappointed, coming in below the $2.42 billion expected by analysts. Despite these challenges, Piper Sandler maintained an Overweight rating for Evolent Health, adjusting the price target to $16 from $17, citing confidence in the company’s value proposition and 2025 adjusted EBITDA forecast of $150 million at the midpoint.
Meanwhile, Citizens JMP raised its price target for Evolent Health to $13 from $12, maintaining a Market Outperform rating. Analyst Constantine Davides expressed optimism about the company’s management and its ability to navigate challenges, suggesting a more predictable profit generation moving forward. Evolent Health’s recent earnings report and the subsequent analyst adjustments reflect its current financial health and future expectations. The company also announced contract amendments expected to yield a $115 million annual improvement in 2025 compared to Q4 2024. Evolent Health retained all partner contracts with its top customers, who account for over 90% of its 2024 revenue, and secured two new revenue agreements in the quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.